Epstein Files Search

EFTA00598930Set 9

2015-10-025p4,184w

ALERT Today, the FDA approved Keytruda (PD-1) with a companion diagnostic Pharmaceuticals — Major & (PD-L1 IHC 22C3 pharmDx test) for second-line PD-L1+ lung cancer Specialty patients ... label, we expect the uptake to be skewed towards (1-212)622-1267 the PD-L1+ non-sq patients. For, BMY, today's Keytruda label further reinforces our view that ... harboring MMR mutations. Dana Flanders, CFA (1-212)622-1256 • Keytruda approved in 2L PD-L1+ NSCLC. The FDA approved M. Morgan Securities LLC Keytruda for use with a companion

https://www.justice.gov/epstein/files/DataSet%209/EFTA00598930.pdf

EFTA00306883Set 9

2014-06-027p4,747w

October. Jessica Fye (1-212) 622-4165 • Merck confirms PD-I efficacy in IL PD-L1+ NSCLC with 47% irRC ORIL First data from Merck's phase lb study ... Merck is initiating a phase III for pembro Dana C Flanders in front-line PD-L1+ NSCLC in September. We note that Bristol initiated a phase ... study ofnivo in PD-L1+ IL lung earlier this year. M. Morgan Securities LLC Pembro head & neck data supports move into phase III. Merck highlighted its head and neck data

https://www.justice.gov/epstein/files/DataSet%209/EFTA00306883.pdf

EFTA00309574Set 9

2014-04-282p1,111w

Bladder Cancer opportunity. ROC.VX Mare pd.* (SwF) MSCI-Fu Ireben41 • Roche continues to explore PD-L1 in further tumour types, although YM 1m 3m 12m there are no timelines ... CAZENOVE Executive Summary Going into ASCO where Roche will present new data for its PD-L1 in bladder cancer on May 31 we have examined the market potential of this ... call Roche seemed more cautious than previously around the Avastin combo opportunity. Beyond PD-L1, phase II ROMULUS data for the Anti-79b in NHL (Non-Hodgkin's lymphoma) also

https://www.justice.gov/epstein/files/DataSet%209/EFTA00309574.pdf

EFTA00822174Set 9

2016-08-052p377w

trial had received no prior systemic treatment for advanced disease and tested positive for PD-L1 expression. The trial randomized 541 patients to receive either Opdivo 3 mg/kg intravenously every ... free survival, as assessed by the Independent Radiology Review Committee, in patients with ≥ 5% PD-L1 tumor expression. EFTA00822174 Daniel Lundquist Healthcare Specialist Sales Global Equities The power of global

https://www.justice.gov/epstein/files/DataSet%209/EFTA00822174.pdf